Labcorp announces 2023 third quarter results

Company updates full-year guidance third quarter revenue grew 6.6% versus last year as the base business grew 14.0%.  results from continuing operations for third quarter versus last year: revenue: $3.06 billion versus $2.87 billion diluted eps: $2.11 versus $3.06 adjusted eps: $3.38 versus $4.01 free cash flow: $170.6 million versus $170.2 million full-year 2023 guidance from continuing operations: adjusted eps of $13.25 to $13.75 and free cash flow excluding spin-related items of $0.85 billion to $0.95 billion advanced hospital and health systems strategy through multiple new agreements launched atn (amyloid-tau-neurodegeneration) profile, a new test to accelerate path to diagnosis of alzheimer's disease burlington, n.c.
LH Ratings Summary
LH Quant Ranking